Calidi Biotherapeutics Inc. Advances Oncology Pipeline and Strategic Goals in 2025
Calidi Biotherapeutics Inc. outlines significant progress in its oncology immunotherapy pipeline and strategic initiatives aimed at enhancing shareholder value and advancing cancer treatment options.
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology firm specializing in systemic oncolytic targeted immunotherapies, has made notable strides in its 2025 pipeline and strategic focus, as detailed in a recent shareholder letter by CEO Eric Poma, PhD. The company has streamlined operations and progressed its RedTail platform, a systemically delivered virotherapy targeting metastatic cancers, with preclinical data presented at AACR and ASCO highlighting its tumor selectivity and immune modulation potential. This progress has spurred partnership discussions and IND-enabling studies for its lead candidate, CLD-401, with an IND filing expected by the end of 2026. Additionally, Calidi has initiated an IND for its intratumoral virotherapy, CLD-201, with Phase I trials anticipated to commence by year-end. Financially, Calidi reported a strong position with $10.6 million in cash and a reduced burn rate at the end of Q1, positioning the company to rapidly advance its innovative oncology treatments while aiming to increase shareholder value.